Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
207.4 USD | +2.44% | +6.39% | -20.08% |
05:33pm | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.